
The PSMA PET radiopharmaceutical 64Cu-SAR-bisPSMA, which previously garnered two FDA fast track designations, more than doubled the detection of PCa lesions in comparison to 68Ga-PSMA-11 in the phase II Co-PSMA trial.
Catch up on the first three episodes of our Molecular Imaging in Focus series featuring interviews with Gary Ulaner, MD, PhD, Louise Emmett, MBChB, FRACP, FAANMS, MD, and Jeremie Calais, MD, PhD.
We take a look back at the first three episodes of our new Molecular Imaging in Focus series with topics ranging from the potential of the emerging radiodiagnostic agent 61Cu-NU101 and recent findings from the Co-PSMA trial with 64Cu-SAR-bisPSMA to the utility of PSMA PET in risk stratification for patients with prostate cancer. Review the slideshow below to watch the first three episodes.





